Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab govitecan versus physician's choice chemotherapy in previously treated recurrent or persistent endometrial cancer
2024-511957-23-00Phase 3Authorised
- Sponsor
- Gilead Sciences
- Start
- Jan 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial of sacituzumab govitecan in endometrial cancer (EC) and endometrial carcinosarcoma (2 arms), sponsored by Gilead Sciences. Primary endpoints: Progression-free survival and Overall survival. Planned start Jan 2025; status: authorised.
02
Drugs
sacituzumab govitecan
03
Conditions
endometrial cancer (EC)endometrial carcinosarcoma
Beyond the preview
Go deeper on 2024-511957-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511957-23-00.